Mass General Hospital

Harvard Medical School

Blog

blog2

New Study at the CWMH: Brexanolone (SAGE-547) for Postpartum Depression

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression.  SAGE-547, now called brexanolone, is a new type of antidepressant: a formulation of allopregnanolone, which is an endogenous, naturally occurring neuroactive steroid and a metabolite of progesterone.  Data from the most recent study of brexanolone was […]

Continue Reading · 0

In Brief: Problem-Solving Education Intervention Reduces Risk of Postpartum Depression

  While many women are at risk for postpartum depression, we continue to struggle in providing adequate support and care to women in this setting, especially socioeconomically disadvantaged women.   In a randomized clinical trial including 230 Head Start mothers, those receiving problem-solving education (PSE) were 60% less likely to develop postpartum depression than those […]

Continue Reading · 0

New Research from the CWMH: Lithium During Pregnancy and Risk of Cardiovascular Malformations

  While we use lithium less commonly now than we have in the past, lithium is still one of the very best mood stabilizers we have.  And with regard to its reproductive safety, we have studies going back nearly 50 years.   In the 1970s, reports from the International Register of Lithium Babies suggested a […]

Continue Reading · 0

Weekly Roundup for June 16, 2017: Recent Publications in Women’s Mental Health

This roundup has some really interesting and clinically relevant  articles.  The first one, from Palomo and colleagues, evaluates risk for cardiovascular malformations in children prenatally exposed to lithium.  Yang and colleagues look at neonatal discontinuation symptoms in children exposed to SNRIs and SSRIs and conclude that they are more related to prematurity than to exposure […]

Continue Reading · 0

Oxcarbazepine (Trileptal) and Pregnancy: Do We Have Enough Information?

  Last week in clinical rounds we discussed a case of a woman with bipolar disorder who was planning a pregnancy.  She had a long history of illness, experiencing primarily depressive episodes since her early 20’s.  The only mood stabilizer that seems to have worked for her has been oxcarbazepine (Trileptal) and she is currently […]

Continue Reading · 0

Psychiatric Clinics of North America: June Issue on Women’s Mental Health

In the field of reproductive psychiatry, we don’t really have any textbooks to rely on.  However, the June issue of the Psychiatric Clinics of North America is devoted to Women’s Mental Health, and it’s pretty much the most comprehensive guide on this topic. With articles from leaders in the field, it covers PMDD, medication use […]

Continue Reading · 0

Weekly Roundup for June 2, 2017: Recent Publications in Women’s Mental Health

Sometimes a weekly roundup turns into a monthly roundup.  Sorry about that.  From  the PACT Consortium, we have a study defining distinct subtypes of perinatal depression which differ in terms of severity and timing of onset. Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. Putnam KT, […]

Continue Reading · 0

Lamotrigine Reduces Risk for Postpartum Relapse in Women with Bipolar Disorder

Numerous studies have demonstrated that women with histories of bipolar disorder are at high risk for postpartum illness.  Because of this increased risk for relapse during the postpartum period, we typically recommend that women with histories of bipolar disorder continue treatment with a mood stabilizer throughout the postpartum period.  Historically, lithium has been the most […]

Continue Reading · 0